Cannabis, essential data and knowledge

 

cdegb.jpg

OFDT, 22 p.
May 2009

Cannabis is the most widely available and most used illicit drug in Europe. However, in terms of consumption, France is among the top list countries, at least among young people. Over the past few years, the public authorities have strengthened their efforts to highlight the dangers of this illicit drug. New communication campaigns have been launched via television and other media.
The aim of the present document is to illustrate the different aspects of the situation of cannabis in France (consumption, market, risks and consequences, public policy, etc.). It is essentially based on the monograph published by the French Monitoring Centre for Drugs and Drug Addiction, Cannabis, données essentielles (July 2007), but also relies on several other publications that were published since then as well as updated data in this field, presented throughout the article as footnotes. It seeks to offer a somewhat updated synthesis of this monograph for the English-speaking public and Internet users.

Under the direction of Jean-Michel Costes

Download the PDF file (222 Ko)

 

 

 

 

 

 

 

 

 

Drugs in Europe


2020 EMCDDA European Drug Report

COVID-19
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2020 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2020

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.